Tactile Systems Technology, Inc. (TCMD) Reaches $31.61 After 8.00% Up Move; WUXI BIOLOGICS CAYMAN ORD CAYMAN (WXIBF) Shorts Increased By 7.85%

February 15, 2018 - By Louis Casey

WUXI BIOLOGICS CAYMAN ORD CAYMAN (OTCMKTS:WXIBF) had an increase of 7.85% in short interest. WXIBF’s SI was 727,900 shares in February as released by FINRA. Its up 7.85% from 674,900 shares previously. It closed at $6.98 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Tactile Systems Technology, Inc. (NASDAQ:TCMD) is a huge mover today! The stock increased 3.88% or $1.18 during the last trading session, reaching $31.61. About 98,516 shares traded. Tactile Systems Technology, Inc. (NASDAQ:TCMD) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 8 months positive chart setup for the $559.55 million company. It was reported on Feb, 15 by Barchart.com. We have $34.14 PT which if reached, will make NASDAQ:TCMD worth $44.76 million more.

Among 2 analysts covering Tactile Systems Tech (NASDAQ:TCMD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tactile Systems Tech had 2 analyst reports since August 22, 2016 according to SRatingsIntel. BTIG Research initiated the stock with “Buy” rating in Monday, August 22 report. On Monday, August 22 the stock rating was initiated by Piperjaffray with “Overweight”.

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices for the treatment of chronic diseases in the United States. The company has market cap of $559.55 million. It offers proprietary Flexitouch system, an at-home solution for lymphedema patients; ACTitouch system, a home solution for chronic venous insufficiency patients; and Entré System, a basic pneumatic compression device used for the at-home treatment of venous disorders, including lymphedema and chronic venous insufficiency. It has a 107.15 P/E ratio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: